Site search
2811 results for '' found
MagnetisMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratum
MagnetisMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratum
/
An International Phase 2, Open-Label, One-Arm, Multi-Center Study to Evaluate Safety and Efficacy of PF-06835375 in Adult Participants with Moderate to Severe Primary Immune Thrombocytopenia (NCT
An International Phase 2, Open-Label, One-Arm, Multi-Center Study to Evaluate Safety and Efficacy of PF-06835375 in Adult Participants with Moderate to Severe Primary Immune Thrombocytopenia (NCT
/
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe
/
BTM utilisation for burn scar contracture - long term outcomes (Trial Not Registered)
BTM utilisation for burn scar contracture - long term outcomes (Trial Not Registered)
/
Breathing Control Training (BCT) as a Treatment for Functional Seizures (FS) – a multi-centre, assessor-blinded, randomised controlled efficacy and acceptability trial (ACTRN12622000525785)
Breathing Control Training (BCT) as a Treatment for Functional Seizures (FS) – a multi-centre, assessor-blinded, randomised controlled efficacy and acceptability trial (ACTRN12622000525785)
/
An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Versus Standard of Care Therapy with A Safety Lead-in of Encorafenib And
An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Versus Standard of Care Therapy with A Safety Lead-in of Encorafenib And
/
A Phase Ib/IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study To Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ro71
A Phase Ib/IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study To Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ro71
/
A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN
A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN
/
An open-label, phase 1 / 2 study to evaluate the safety, pharmacokinetics and preliminary anti-tumour activity of Englumafusp Alfa [RO7227166, A CD19 targeted 4-1BB ligand] in combination with Ob
An open-label, phase 1 / 2 study to evaluate the safety, pharmacokinetics and preliminary anti-tumour activity of Englumafusp Alfa [RO7227166, A CD19 targeted 4-1BB ligand] in combination with Ob
/
Bringing Optimised COVID-19 vaccine Schedules To Immunocompromised populations (BOOST IC) an adaptive randomised controlled clinical trial (NCT05556720)
Bringing Optimised COVID-19 vaccine Schedules To Immunocompromised populations (BOOST IC) an adaptive randomised controlled clinical trial (NCT05556720)
/